Please assess the completion status of the following clinical trial:

Trial Title: Study of Velcade and Thalidomide in Patients With Myelodysplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Myelodysplastic syndrome with a IPSS score of 0.5 or greater~* May have had prior chemo/radiotherapy for another malignancy or myelodysplasia~* ECOG performance status of 0-2~* Life expectancy greater than 3 months~* Total bilirubin \</+ 2xULN~* ALT and AST \</+ 3xULN~* Calculated creatinine clearance \> 30 ml/min~* Use of appropriate method of contraception during the study~* ANC \> 0.5 x 10(9)~* Platelet count \> 30 x 10(9)~* Consideration of treatment with 5 azacytidine is encouraged by not required~Exclusion Criteria:~* Ejection fraction \< 40%~* myocardial infarction within 6 months of enrollment of New York Heart Association Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Women who are pregnant or breast-feeding~* Major surgery within 4 weeks prior to enrollment~* \>/= grade 2 peripheral neuropathy within 14 days prior to enrollment~* Uncontrolled intercurrent illness~* Serious medical or psychiatric illness that could potentially interfere with the completion of treatment~* Hypersensitivity to bortezomib, boron, or mannitol~* Received an investigational drug within 14 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).